Type 1 diabetes cannot be fully reversed today, but several treatments are getting closer to what researchers call a “functional cure,” where the body produces its own insulin again using transplanted or lab-grown cells. The distinction matters: a true reversal would mean stopping the autoimmune attack and restoring your original beta cells, while a functional cure replaces those cells through other means. Both paths are being pursued, and some have already reached human trials with striking results.
Why Type 1 Diabetes Is So Hard to Reverse
Type 1 diabetes is fundamentally different from type 2. In type 2, the insulin-producing beta cells in your pancreas are still alive but underperforming. In type 1, your immune system targets and destroys those cells directly. By the time most people are diagnosed, a large portion of their beta cells are gone.
Recent research has complicated this picture in an interesting way. Some beta cells may not actually die during the immune attack. Instead, they appear to “dedifferentiate,” essentially disguising themselves by shedding the features that make them targets. These surviving cells stop producing insulin, but they’re technically still there, hiding from the immune system. Researchers have found that these resilient beta cells express lower levels of the proteins the immune system recognizes and higher levels of proteins that signal the immune system to leave them alone. This discovery raises a tantalizing question: if those cells could be coaxed back into producing insulin while the immune attack is kept in check, something closer to true reversal might be possible.
But that’s still theoretical. For now, any approach to restoring insulin production has to solve two problems simultaneously: getting functional beta cells into the body, and preventing the immune system from destroying them again.
The Honeymoon Phase: A Window of Natural Insulin Production
If you were recently diagnosed, you may already be experiencing something that feels like partial reversal. The “honeymoon phase” occurs when some beta cells survive the initial immune attack and continue producing small amounts of insulin. During this period, you need less injected insulin and blood sugar is easier to manage. It typically lasts several months, though it can stretch to one or two years. It always ends, because the immune system continues its slow destruction of the remaining cells. But this phase demonstrates that even a small number of working beta cells can meaningfully improve blood sugar control.
Stem Cell Therapy: The Closest Thing to a Functional Cure
The most dramatic results in type 1 diabetes research right now come from stem cell-derived beta cell transplants. The therapy called VX-880, developed by Vertex Pharmaceuticals, takes stem cells and transforms them into insulin-producing cells in the lab, then infuses them into patients.
In a clinical trial of 12 participants who all started with no detectable insulin production and frequent dangerous blood sugar crashes, every single one began producing insulin by day 90 after the infusion. That insulin production was durable through 12 months. On average, participants reduced their injected insulin by 92%. Ten of the 12, or 83%, stopped needing injected insulin entirely. The median time participants remained free of injected insulin was 232 days, with some reaching over 400 days.
These numbers are remarkable, but there’s a significant catch. VX-880 currently requires immunosuppressive drugs to prevent the body from rejecting the transplanted cells, and those drugs carry their own serious risks, including increased vulnerability to infections and certain cancers. The therapy is still in clinical trials and not yet available outside of research settings.
Islet Cell Transplantation: The Longer Track Record
Before stem cell approaches, researchers pursued transplanting islet cells (the clusters in the pancreas that contain beta cells) from organ donors. This procedure has been performed for over two decades, and the data shows it works for some people. With the most effective immune-suppression protocols, about 50% of recipients remain insulin-independent at five years. That’s comparable to the success rate of a full pancreas transplant.
The limitation is supply. Donor islets are scarce, and a single recipient often needs islets from two or more donors. This is exactly why stem cell-derived cells are so promising: they could be manufactured at scale without relying on organ donors.
Protecting Transplanted Cells Without Immune Suppression
The biggest obstacle to making cell replacement therapies practical for more people is eliminating the need for lifelong immunosuppressive drugs. Several approaches are being developed to solve this.
Encapsulation involves wrapping transplanted cells in a protective material that lets insulin and glucose pass through but blocks immune cells from making direct contact. Think of it as a microscopic force field. These capsules prevent the immune system’s attack cells from reaching the transplanted beta cells, block antibodies from triggering destruction, and hide the molecular markers that flag the cells as foreign. Newer designs also incorporate signals that actively tell nearby immune cells to stand down.
Gene editing offers another route. Researchers can modify transplanted cells to delete the surface proteins that the immune system uses to identify them as foreign, while adding proteins like CD47 that prevent immune attack. In animal studies, cells engineered this way have survived and reversed diabetes without any immunosuppressive drugs.
A third strategy cotransplants specialized immune-modulating cells alongside the beta cells. These accessory cells are engineered to produce proteins that create a zone of immune tolerance around the transplant, protecting it locally rather than suppressing the entire immune system.
Slowing the Disease Before It Starts
For people who haven’t yet developed full type 1 diabetes but are at high risk (identified through blood tests that detect autoantibodies), there is now an FDA-approved option to delay the disease. Teplizumab (brand name Tzield) is an immunotherapy that calms the specific immune response attacking beta cells. It’s approved for people ages one and older who are in “stage 2” type 1 diabetes, meaning they have autoantibodies and abnormal blood sugar but don’t yet need insulin.
A single course of teplizumab delays the onset of insulin-dependent diabetes by an average of two to three years. Over a third of people who received it in clinical trials remained free of clinical diabetes for more than seven years, and some have gone over 10 years without progressing. This isn’t reversal, but for a child or teenager, delaying insulin dependence by several years can be transformative for quality of life during critical developmental periods.
What “Reversal” Realistically Looks Like Today
If you’re living with type 1 diabetes right now and searching for reversal, here is the honest landscape. No commercially available treatment can restore your body’s insulin production today. The stem cell results are genuinely exciting but still experimental. Teplizumab only helps people who haven’t yet progressed to full diabetes. Islet transplantation is limited by donor supply and the burden of immunosuppression.
What is available and improving rapidly is the technology to manage type 1 diabetes with less daily effort. Automated insulin delivery systems, which pair continuous glucose monitors with insulin pumps that adjust dosing automatically, have advanced significantly. Newer systems like the twiist AID system are now available in the U.S., and longer-lasting infusion sets that only need changing every seven days are on the way. These don’t reverse the disease, but they reduce the constant mental load of managing it.
The gap between “managing type 1 diabetes” and “functionally curing it” is narrowing faster than at any point in the disease’s history. The combination of stem cell-derived beta cells, encapsulation or gene editing to avoid immunosuppression, and immunotherapies to quiet the autoimmune attack represents a plausible path to a functional cure within the coming years. For people diagnosed today, particularly children, the realistic possibility exists that they may not need to manage this disease manually for their entire lives.